Ultragenyx Pharmaceutical Inc
RARE31.035USD
-10.405-25.11%
Close 07/10, 16:00（ET）Quotes delayed by 15 min
2.91BMarket Cap
LossP/E TTM
More Details of Ultragenyx Pharmaceutical Inc Company
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
Company Info
Ticker SymbolRARE
Company nameUltragenyx Pharmaceutical Inc
IPO dateJan 31, 2014
Founded at2011
CEODr. Emil D. Kakkis, M.D., Ph.D.
Number of employees1294
Security typeOrdinary Share
Fiscal year-endJan 31
Address60 Leveroni Ct
CityNOVATO
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94949
Phone14154838800
Websitehttps://www.ultragenyx.com/
Ticker SymbolRARE
IPO dateJan 31, 2014
Founded at2011
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Emil D. Kakkis, M.D., Ph.D.
Dr. Emil D. Kakkis, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.69M
-1.17%
Mr. Dennis Karl Huang
Mr. Dennis Karl Huang
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
107.20K
+41.78%
Mr. Erik Harris
Mr. Erik Harris
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
41.99K
+83.47%
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
27.34K
+26.57%
Mr. Michael A. Narachi
Mr. Michael A. Narachi
Independent Director
Independent Director
27.34K
+26.57%
Dr. Shehnaaz Suliman, M.D.
Dr. Shehnaaz Suliman, M.D.
Independent Director
Independent Director
20.59K
+38.64%
Dr. Amrit Ray, M.D.
Dr. Amrit Ray, M.D.
Independent Director
Independent Director
18.02K
+46.74%
Mr. Howard Horn
Mr. Howard Horn
Chief Financial Officer, Executive Vice President, Corporate Strategy
Chief Financial Officer, Executive Vice President, Corporate Strategy
15.69K
-83.00%
Mr. John R. Pinion, II
Mr. John R. Pinion, II
Chief Quality Officer, Executive Vice President - Translational Sciences
Chief Quality Officer, Executive Vice President - Translational Sciences
--
--
Dr. Deborah L. Dunsire, M.D.
Dr. Deborah L. Dunsire, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Emil D. Kakkis, M.D., Ph.D.
Dr. Emil D. Kakkis, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.69M
-1.17%
Mr. Dennis Karl Huang
Mr. Dennis Karl Huang
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
107.20K
+41.78%
Mr. Erik Harris
Mr. Erik Harris
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
41.99K
+83.47%
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
27.34K
+26.57%
Mr. Michael A. Narachi
Mr. Michael A. Narachi
Independent Director
Independent Director
27.34K
+26.57%
Dr. Shehnaaz Suliman, M.D.
Dr. Shehnaaz Suliman, M.D.
Independent Director
Independent Director
20.59K
+38.64%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
By BusinessUSD
Name
Revenue
Proportion
Crysvita
55.08M
39.54%
Crysvita royalty revenue
47.78M
34.31%
Dojolvi
17.01M
12.21%
Evkeeza
11.03M
7.92%
Mepsevii
8.39M
6.02%
By RegionUSD
Name
Revenue
Proportion
North America
57.79M
41.49%
Latin America
54.89M
39.40%
Europe
23.33M
16.75%
Japan
3.29M
2.36%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Crysvita
55.08M
39.54%
Crysvita royalty revenue
47.78M
34.31%
Dojolvi
17.01M
12.21%
Evkeeza
11.03M
7.92%
Mepsevii
8.39M
6.02%
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.55%
BlackRock Institutional Trust Company, N.A.
5.20%
Sands Capital Management, LLC
4.40%
T. Rowe Price Associates, Inc.
3.32%
Kakkis (Emil D)
2.85%
Other
73.68%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.55%
BlackRock Institutional Trust Company, N.A.
5.20%
Sands Capital Management, LLC
4.40%
T. Rowe Price Associates, Inc.
3.32%
Kakkis (Emil D)
2.85%
Other
73.68%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
44.96%
Investment Advisor
27.79%
Hedge Fund
21.16%
Individual Investor
3.56%
Research Firm
1.72%
Sovereign Wealth Fund
1.02%
Private Equity
0.70%
Pension Fund
0.65%
Bank and Trust
0.28%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
627
96.81M
102.40%
-2.03M
2025Q1
652
96.83M
102.45%
-3.19M
2024Q4
645
94.29M
102.32%
-4.54M
2024Q3
633
93.51M
101.49%
-6.93M
2024Q2
618
95.17M
101.90%
+3.05M
2024Q1
605
86.17M
101.67%
-4.74M
2023Q4
588
86.44M
105.27%
+5.64M
2023Q3
574
75.90M
106.07%
-3.60M
2023Q2
591
75.05M
105.07%
-3.13M
2023Q1
609
74.12M
105.56%
-2.85M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
9.98M
10.55%
-38.64K
-0.39%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.91M
5.2%
-49.62K
-1.00%
Mar 31, 2025
Sands Capital Management, LLC
4.16M
4.4%
-134.44K
-3.13%
Mar 31, 2025
T. Rowe Price Associates, Inc.
3.14M
3.32%
+698.80K
+28.65%
Mar 31, 2025
Kakkis (Emil D)
2.69M
2.85%
-31.78K
-1.17%
Mar 07, 2025
State Street Global Advisors (US)
2.62M
2.77%
-104.13K
-3.82%
Mar 31, 2025
Wellington Management Company, LLP
2.45M
2.59%
-8.04K
-0.33%
Mar 31, 2025
ClearBridge Investments, LLC
2.26M
2.39%
-62.50K
-2.69%
Mar 31, 2025
Adage Capital Management, L.P.
2.15M
2.27%
+965.92K
+81.64%
Mar 31, 2025
Federated Hermes Global Investment Management Corp.
2.05M
2.17%
+3.00K
+0.15%
Mar 31, 2025
View more
Related ETFs
Updated: Sun, Jul 6
Updated: Sun, Jul 6
Name
Proportion
Global X Genomics & Biotechnology ETF
3.89%
Motley Fool Small-Cap Growth ETF
3%
Motley Fool Mid-Cap Growth ETF
2.01%
Franklin Genomic Advancements ETF
2%
Virtus LifeSci Biotech Products ETF
1.84%
Touchstone Sands Capital US Select Growth ETF
1.26%
WisdomTree BioRevolution Fund
1.12%
SPDR S&P Biotech ETF
0.77%
Putnam Sustainable Future ETF
0.63%
Goldman Sachs Future Health Care Equity ETF
0.6%
View more
Global X Genomics & Biotechnology ETF
Proportion3.89%
Motley Fool Small-Cap Growth ETF
Proportion3%
Motley Fool Mid-Cap Growth ETF
Proportion2.01%
Franklin Genomic Advancements ETF
Proportion2%
Virtus LifeSci Biotech Products ETF
Proportion1.84%
Touchstone Sands Capital US Select Growth ETF
Proportion1.26%
WisdomTree BioRevolution Fund
Proportion1.12%
SPDR S&P Biotech ETF
Proportion0.77%
Putnam Sustainable Future ETF
Proportion0.63%
Goldman Sachs Future Health Care Equity ETF
Proportion0.6%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
